Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap

Source: IDWeek 2021: Clinical Impact of New Data*
September 29 - October 3, 2021; Virtual
Listen to expert insights from Darcy Wooten, MD, on updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.
Darcy Wooten, MD
Released: October 11, 2021

In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

  • A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
  • Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
  • Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
  • Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
  • Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
  • The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

Information on this Educational Activity

Faculty

Darcy Wooten, MD

Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022
Introductory Case
Question and Answer Session

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Expert selections of data for state-of-the-art switch strategies in virologically suppressed patients.

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Paul E. Sax, MD Released: May 6, 2022

Expert analysis of barriers and solutions to PrEP uptake in key populations.

Joseph J. Eron, Jr., MD Gregory Huhn, MD, MPHTM Jeffrey Kwong, DNP, MPH, FAANP, FAAN Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP Released: May 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings